In inflammatory bowel disease (IBD), GPR109a signaling pathway may inhibit the microbial-induced production of multiple inflammatory cytokines by DCs, including IL-23 in colon, thereby inhibiting ILC3s to suppress inflammation (Fig. 1) (29). Here, HCAR2 is linked to inflammatory bowel disease.